279
Participants
Start Date
March 5, 2015
Primary Completion Date
September 16, 2027
Study Completion Date
September 16, 2027
ruxolitinib
ruxolitinib tablets or pediatric oral solution - participants continue ruxolitinib as they received in parent study
panobinostat
panobinostat capsules - participants to continue receiving panobinostat in combination with ruxolitinib as per the parent study
Novartis Investigative Site, Sofia
Novartis Investigative Site, Sofia
Novartis Investigative Site, Darlinghurst
Novartis Investigative Site, Soweto
Novartis Investigative Site, Antwerp
Novartis Investigative Site, St Leonards
Novartis Investigative Site, Leuven
Novartis Investigative Site, Box Hill
Novartis Investigative Site, Clayton
Novartis Investigative Site, Franston
Novartis Investigative Site, Liège
Novartis Investigative Site, Plovdiv
Novartis Investigative Site, Herston
Novartis Investigative Site, Debrecen
Novartis Investigative Site, Wooloongabba
Novartis Investigative Site, Bedford Park
Novartis Investigative Site, Pleven
Novartis Investigative Site, Perth
Novartis Investigative Site, Kecskemét
Novartis Investigative Site, Kaposvár
Novartis Investigative Site, Cape Town
Novartis Investigative Site, Bruges
Novartis Investigative Site, Orbassano
Novartis Investigative Site, Bangkok
Novartis Investigative Site, Rozzano
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Novartis Investigative Site, Milan
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Varese
Novartis Investigative Site, Brescia
Novartis Investigative Site, Pavia
Novartis Investigative Site, Pamplona
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Izmir
Novartis Investigative Site, Salamanca
Novartis Investigative Site, Kayseri
Novartis Investigative Site, Magdeburg
Novartis Investigative Site, Bologna
Novartis Investigative Site, Florence
Novartis Investigative Site, Aachen
Novartis Investigative Site, Mainz
Novartis Investigative Site, Ancona
Novartis Investigative Site, Monterrey
Novartis Investigative Site, Bari
Novartis Investigative Site, San Giovanni Rotondo
Novartis Investigative Site, Paris
Novartis Investigative Site, Napoli
Novartis Investigative Site, Ulm
Novartis Investigative Site, Reggio Calabria
Novartis Investigative Site, Palermo
Novartis Investigative Site, Beijing
Novartis Investigative Site, Moscow
Novartis Investigative Site, Moscow
Novartis Investigative Site, Moscow
Novartis Investigative Site, Petrozavodsk
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Hangzhou
Novartis Investigative Site, Pune
Novartis Investigative Site, Afula
Novartis Investigative Site, Viña del Mar
Novartis Investigative Site, Santiago
Novartis Investigative Site, Santiago
Novartis Investigative Site, Jerusalem
Novartis Investigative Site, Toronto
Novartis Investigative Site, Dresden
Novartis Investigative Site, Dresden
Novartis Investigative Site, Jena
Novartis Investigative Site, Athens
Novartis Investigative Site, Pátrai
Novartis Investigative Site, Budapest
Novartis Investigative Site, Szeged
Novartis Investigative Site, Szombathely
Novartis Investigative Site, Roma
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Isehara
Novartis Investigative Site, Suita
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Osaka
Novartis Investigative Site, Beirut
Novartis Investigative Site, Gliwice
Novartis Investigative Site, Wroclaw
Novartis Investigative Site, Lisbon
Novartis Investigative Site, Lisbon
Novartis Investigative Site, Pretoria
Novartis Investigative Site, Pretoria
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Huddinge
Novartis Investigative Site, Luleå
Novartis Investigative Site, Lund
Novartis Investigative Site, Uddevalla
Novartis Investigative Site, Ankara
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY